Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04840342 · ClinicalTrials.gov registry record · Phase 4

MR Antagonist and LSD1

A Phase 4 study of Hypertension and Mineralocorticoid Excess, sponsored by Brigham and Women's Hospital.

Active
Registry status
Phase 4
Development phase
300
Enrollment target
1
Study location

NCT04840342 is a Phase 4 study of Hypertension and Mineralocorticoid Excess that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04840342, a Phase 4 study of Hypertension and Mineralocorticoid Excess, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (\~30%) of the essential hypertension population (Black LSD1 risk allele hypertensives).

Conditions Studied

Hypertension Mineralocorticoid Excess

Interventions

  • DRUG Amlodipine
  • DRUG Eplerenone

Study Locations (1)

Massachusetts

  • Brigham and Women's - Boston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2022-02-03
Est. Completion 2026-06
Phase Phase 4

Sponsor

Brigham and Women's Hospital

937 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04840342

The ClinicalTrials.gov registry entry for NCT04840342 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Amlodipine is the first listed.

NCT04840342 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04840342 about?

NCT04840342 is a clinical study titled "MR Antagonist and LSD1". Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood p...

What is the current status of trial NCT04840342?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2022-02-03. Estimated completion is 2026-06.

What conditions does trial NCT04840342 study?

This clinical trial studies the following conditions: Hypertension, Mineralocorticoid Excess.

What interventions are being tested in trial NCT04840342?

The interventions under investigation include: Amlodipine (DRUG), Eplerenone (DRUG).

Who is sponsoring clinical trial NCT04840342?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04840342 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Mineralocorticoid Excess

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.